HspB8 prevents aberrant phase transitions of FUS by chaperoning its folded RNA binding domain

  1. Edgar E Boczek
  2. Julius Fürsch
  3. Marie Laura Niedermeier
  4. Louise Jawerth
  5. Marcus Jahnel
  6. Martine Ruer-Gruß
  7. Kai-Michael Kammer
  8. Peter Heid
  9. Laura Mediani
  10. Jie Wang
  11. Xiao Yan
  12. Andrej Pozniakovski
  13. Ina Poser
  14. Daniel Mateju
  15. Lars Hubatsch
  16. Serena Carra
  17. Dr. Simon Alberti
  18. Anthony A Hyman
  19. Florian Stengel  Is a corresponding author
  1. Max Planck Institute of Molecular Cell Biology and Genetics, Germany
  2. University of Konstanz, Germany
  3. Max Planck Institute for the Physics of Complex Systems, Germany
  4. Biotec, TU Dresden, Germany
  5. University of Modena and Reggio Emilia, Italy

Abstract

Aberrant liquid-to-solid phase transitions of biomolecular condensates have been linked to various neurodegenerative diseases. However, the underlying molecular interactions that drive aging remain enigmatic. Here, we develop quantitative time-resolved crosslinking mass spectrometry to monitor protein interactions and dynamics inside condensates formed by the protein fused in sarcoma (FUS). We identify misfolding of the RNA recognition motif (RRM) of FUS as a key driver of condensate ageing. We demonstrate that the small heat shock protein HspB8 partitions into FUS condensates via its intrinsically disordered domain and prevents condensate hardening via condensate-specific interactions that are mediated by its α-crystallin domain (αCD). These αCD-mediated interactions are altered in a disease-associated mutant of HspB8, which abrogates the ability of HspB8 to prevent condensate hardening. We propose that stabilizing aggregation-prone folded RNA-binding domains inside condensates by molecular chaperones may be a general mechanism to prevent aberrant phase transitions.

Data availability

All data generated or analysed during this study are included in this published article (and its supplementary information files). The MS data (raw files, xQuest, xTract and in-house quantitation output files) have been deposited to the ProteomeXchange Consortium via the PRIDE (60) partner repository with the dataset identifier PXD021114 (Username: reviewer33076@ebi.ac.uk; Password: 5atfkbP8) and PXD021115 (Username: reviewer54149@ebi.ac.uk; Password: UZW7Gnr5).

The following data sets were generated

Article and author information

Author details

  1. Edgar E Boczek

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Edgar E Boczek, is currently an employee of Dewpoint Therapeutics..
  2. Julius Fürsch

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  3. Marie Laura Niedermeier

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  4. Louise Jawerth

    Max Planck Institute for the Physics of Complex Systems, Dresden, Germany
    Competing interests
    No competing interests declared.
  5. Marcus Jahnel

    Biophysics, Biotec, TU Dresden, Dresden, Germany
    Competing interests
    No competing interests declared.
  6. Martine Ruer-Gruß

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  7. Kai-Michael Kammer

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  8. Peter Heid

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  9. Laura Mediani

    University of Modena and Reggio Emilia, Modena, Italy
    Competing interests
    No competing interests declared.
  10. Jie Wang

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  11. Xiao Yan

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  12. Andrej Pozniakovski

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  13. Ina Poser

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Ina Poser, is currently an employee of Dewpoint Therapeutics.
  14. Daniel Mateju

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    No competing interests declared.
  15. Lars Hubatsch

    Max Planck Institute for the Physics of Complex Systems, Dresden, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1934-7437
  16. Serena Carra

    University of Modena and Reggio Emilia, Modena, Italy
    Competing interests
    No competing interests declared.
  17. Dr. Simon Alberti

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Dr. Simon Alberti, is a shareholder, consultant and member of the scientific advisory board for Dewpoint Therapeutics..
  18. Anthony A Hyman

    Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
    Competing interests
    Anthony A Hyman, is cofounder, shareholder, consultant and member of the scientific advisory board for Dewpoint Therapeutics..
  19. Florian Stengel

    Department of Biology, University of Konstanz, Konstanz, Germany
    For correspondence
    Florian.Stengel@uni-konstanz.de
    Competing interests
    Florian Stengel, is a consultant and member of the scientific advisory board for Dewpoint Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1447-4509

Funding

Deutsche Forschungsgemeinschaft (STE 2517/1-1)

  • Florian Stengel

Konstanz Research School Chemical Biology (Chemicals and small Equipment Purchase)

  • Florian Stengel

Deutsche Forschungsgemeinschaft (Cluster of Excellence Physics of Life"")

  • Dr. Simon Alberti

Deutsche Forschungsgemeinschaft (Cluster of Excellence Physics of Life"")

  • Anthony A Hyman

EU Joint Programme – Neurodegenerative Disease Research (Neurodegenerative Disease Research (JPND))

  • Serena Carra

EU Joint Programme – Neurodegenerative Disease Research (Neurodegenerative Disease Research (JPND))

  • Dr. Simon Alberti

AriSLA Foundation (Granulopathy and MLOpathy)

  • Serena Carra

MAECI (Dissolve_ALS)

  • Serena Carra

MIUR (E91I18001480001)

  • Serena Carra

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Boczek et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,005
    views
  • 552
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Edgar E Boczek
  2. Julius Fürsch
  3. Marie Laura Niedermeier
  4. Louise Jawerth
  5. Marcus Jahnel
  6. Martine Ruer-Gruß
  7. Kai-Michael Kammer
  8. Peter Heid
  9. Laura Mediani
  10. Jie Wang
  11. Xiao Yan
  12. Andrej Pozniakovski
  13. Ina Poser
  14. Daniel Mateju
  15. Lars Hubatsch
  16. Serena Carra
  17. Dr. Simon Alberti
  18. Anthony A Hyman
  19. Florian Stengel
(2021)
HspB8 prevents aberrant phase transitions of FUS by chaperoning its folded RNA binding domain
eLife 10:e69377.
https://doi.org/10.7554/eLife.69377

Share this article

https://doi.org/10.7554/eLife.69377

Further reading

    1. Biochemistry and Chemical Biology
    Daljit Sangar, Elizabeth Hill ... Jan Bieschke
    Research Article Updated

    Prions replicate via the autocatalytic conversion of cellular prion protein (PrPC) into fibrillar assemblies of misfolded PrP. While this process has been extensively studied in vivo and in vitro, non-physiological reaction conditions of fibril formation in vitro have precluded the identification and mechanistic analysis of cellular proteins, which may alter PrP self-assembly and prion replication. Here, we have developed a fibril formation assay for recombinant murine and human PrP (23-231) under near-native conditions (NAA) to study the effect of cellular proteins, which may be risk factors or potential therapeutic targets in prion disease. Genetic screening suggests that variants that increase syntaxin-6 expression in the brain (gene: STX6) are risk factors for sporadic Creutzfeldt–Jakob disease. Analysis of the protein in NAA revealed, counterintuitively, that syntaxin-6 is a potent inhibitor of PrP fibril formation. It significantly delayed the lag phase of fibril formation at highly sub-stoichiometric molar ratios. However, when assessing toxicity of different aggregation time points to primary neurons, syntaxin-6 prolonged the presence of neurotoxic PrP species. Electron microscopy and super-resolution fluorescence microscopy revealed that, instead of highly ordered fibrils, in the presence of syntaxin-6 PrP formed less-ordered aggregates containing syntaxin-6. These data strongly suggest that the protein can directly alter the initial phase of PrP self-assembly and, uniquely, can act as an ‘anti-chaperone’, which promotes toxic aggregation intermediates by inhibiting fibril formation.

    1. Biochemistry and Chemical Biology
    Aleksandar Bartolome, Julia C Heiby ... Alessandro Ori
    Tools and Resources

    Proteasomes are essential molecular machines responsible for the degradation of proteins in eukaryotic cells. Altered proteasome activity has been linked to neurodegeneration, auto-immune disorders and cancer. Despite the relevance for human disease and drug development, no method currently exists to monitor proteasome composition and interactions in vivo in animal models. To fill this gap, we developed a strategy based on tagging of proteasomes with promiscuous biotin ligases and generated a new mouse model enabling the quantification of proteasome interactions by mass spectrometry. We show that biotin ligases can be incorporated in fully assembled proteasomes without negative impact on their activity. We demonstrate the utility of our method by identifying novel proteasome-interacting proteins, charting interactomes across mouse organs, and showing that proximity-labeling enables the identification of both endogenous and small-molecule-induced proteasome substrates.